Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)
4.20 x 5 4.50 x 12
Post-market by (Cboe BZX)
4.26 -0.43 (-9.17%) 04/10/25 [NYSE]
4.20 x 5 4.50 x 12
Post-market 4.48 +0.22 (+5.16%) 18:30 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.21
Day High
4.61
Open 4.57
Previous Close 4.69 4.69
Volume 733,097 733,097
Avg Vol 1,270,560 1,270,560
Stochastic %K 18.83% 18.83%
Weighted Alpha -31.23 -31.23
5-Day Change -0.57 (-11.80%) -0.57 (-11.80%)
52-Week Range 1.82 - 15.10 1.82 - 15.10
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 254,841
  • Shares Outstanding, K 54,337
  • Annual Sales, $ 1,044 M
  • Annual Income, $ -190,600 K
  • EBIT $ -44 M
  • EBITDA $ 73 M
  • 60-Month Beta 2.14
  • Price/Sales 0.22
  • Price/Cash Flow 2.23
  • Price/Book 0.48

Options Overview Details

View History
  • Implied Volatility 363.43% ( +227.46%)
  • Historical Volatility 88.29%
  • IV Percentile 98%
  • IV Rank 68.86%
  • IV High 509.14% on 04/04/25
  • IV Low 41.21% on 09/11/24
  • Put/Call Vol Ratio 0.22
  • Today's Volume 572
  • Volume Avg (30-Day) 323
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 7,900
  • Open Int (30-Day) 10,511

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.70
  • Number of Estimates 2
  • High Estimate 1.14
  • Low Estimate 0.27
  • Prior Year 0.59
  • Growth Rate Est. (year over year) +18.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.02 +5.97%
on 04/09/25
Period Open: 5.62
6.36 -33.02%
on 03/12/25
-1.36 (-24.20%)
since 03/10/25
3-Month
4.02 +5.97%
on 04/09/25
Period Open: 9.88
11.98 -64.44%
on 01/24/25
-5.62 (-56.88%)
since 01/10/25
52-Week
1.82 +134.05%
on 04/18/24
Period Open: 2.23
15.10 -71.79%
on 07/30/24
+2.03 (+91.03%)
since 04/10/24

Most Recent Stories

More News
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?

Share price of JAZZ Pharmaceuticals JAZZ hit $102.82 on Tuesday, close to its 52-week low of $99.06.This decline is attributable to the significant downturn in the broader biotech/drug sector due to the...

JAZZ : 102.05 (-7.33%)
EBS : 4.26 (-9.17%)
CMRX : 8.53 (unch)
Emergent BioSolutions Announces Stock Repurchase Program

EBS : 4.26 (-9.17%)
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

EBS : 4.26 (-9.17%)
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

HIK.LN : 1,839.000 (+3.66%)
EBS : 4.26 (-9.17%)
HKMPY : 48.6000 (+3.23%)
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

EBS : 4.26 (-9.17%)
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

EBS : 4.26 (-9.17%)
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

EBS : 4.26 (-9.17%)
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

EBS : 4.26 (-9.17%)
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

EBS : 4.26 (-9.17%)
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

Jazz Pharmaceuticals JAZZ announced that it has entered into a definitive agreement to acquire all the outstanding shares of clinical-stage biotech Chimerix CMRX for $8.55 per share in cash, aggregating...

JAZZ : 102.05 (-7.33%)
EBS : 4.26 (-9.17%)
CMRX : 8.53 (unch)

Business Summary

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside...

See More

Key Turning Points

3rd Resistance Point 4.91
2nd Resistance Point 4.76
1st Resistance Point 4.51
Last Price 4.26
1st Support Level 4.11
2nd Support Level 3.96
3rd Support Level 3.71

See More

52-Week High 15.10
Fibonacci 61.8% 10.03
Fibonacci 50% 8.46
Fibonacci 38.2% 6.89
Last Price 4.26
52-Week Low 1.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar